Trial · NCT03315689
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Double Blind Period: ATI-50002 Levels in Scalp Biopsy (ng/g) - Pharmacodynamic (PD) Population at Day 2 and Day 29 | Day 2 - Day 29 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | ng/g | MEAN |
| SECONDARY | Open Label Extension: Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 52 | Baseline - Week 52 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 40 | Baseline - Week 40 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 28 | Baseline - Week 28 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Change From Baseline in Alopecia Density and Extent Score (ALODEX) at Week 28 | Baseline - Week 28 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Change From Baseline in Alopecia Density and Extent Score (ALODEX) at Week 40 | Baseline - Week 40 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Change From Baseline in Alopecia Density and Extent Score (ALODEX) at Week 52 | Baseline - Week 52 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change in Subject's Eyebrow Assessment (SEA) at Week 28 | Week 4 - Week 28 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change in Subject's Eyebrow Assessment (SEA) at Week 40 | Week 4 - Week 40 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change in Subject's Eyebrow Assessment (SEA) at Week 52 | Week 4 - Week 52 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change in Clinician's Eyebrow Assessment (CEA) at Week 28 | Week 4 - Week 28 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change in Clinician's Eyebrow Assessment (CEA) at Week 40 | Week 4 - Week 40 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Mean Change in Clinician's Eyebrow Assessment (CEA) at Week 52 | Week 4 - Week 52 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | score on a scale | MEAN |
| SECONDARY | Open Label Extension: Subject Global Impression of Treatment Satisfaction (SGIS) Week 28 | Week 28 | All patients who have a valid assessment at the timepoint being reported are included. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Open Label Extension: Subject Global Impression of Treatment Satisfaction (SGIS) Week 40 | Week 40 | All patients who have a valid assessment at the timepoint being reported are included. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Open Label Extension: Subject Global Impression of Treatment Satisfaction (SGIS) Week 52 | Week 52 | All patients who have a valid assessment at the timepoint being reported are included. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Open Label Extension: Severity of Alopecia Tool (SALT) Scores, Relative Percent Regrowth (%) at Week 24 From Baseline | Baseline - Week 24 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | percent change | MEAN |
| SECONDARY | Open Label Extension: Severity of Alopecia Tool (SALT Scores), Relative Percent Regrowth (%) at Week 40 From Baseline | Baseline - Week 40 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | percent change | MEAN |
| SECONDARY | Open Label Extension: The Severity of Alopecia Tool (SALT) Scores, Relative Percent Regrowth (%) at Week 52 From Baseline | Baseline - Week 52 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | percent change | MEAN |
| SECONDARY | Open Label Extension: The Alopecia Density and Extent (ALODEX) Scores, Relative Percent Regrowth (%) at 24 Weeks | Baseline - Week 24 | All randomized patients who have a valid assessment at baseline and the subsequent timepoint being reported are included. | percent change | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03315689/outcomes